September 2017 Journal Club Meeting
Originally presented September 21, 2017
Presenters & Articles
Stephen Farley, PharmD
PGY2 Oncology Resident
Roswell Park Cancer Institute, Buffalo, NY
Enasidenib in mutant—IDH2 relapsed or refractory acute myeloid leukemia
Kaitlyn Hughes, PharmD
PGY2 Pharmacy Resident in Oncology
Aurora Health Care Metro Inc., Milwaukee, WI
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small Cell Lung Cancer
This free event is open to HOPA members and non-members.
Listen to this webinar.